There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Morphosys Ag (MOR – Research Report) and Enanta Pharmaceuticals (ENTA – Research Report) with bullish sentiments.
Morphosys Ag (MOR)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Morphosys Ag, with a price target of $17.00. The company’s shares closed last Monday at $5.86.
According to TipRanks.com, Butler has 0 stars on 0-5 stars ranking scale with an average return of
Morphosys Ag has an analyst consensus of Strong Buy, with a price target consensus of $13.11, representing a 123.3% upside. In a report issued on November 6, Wells Fargo also maintained a Buy rating on the stock with a $17.00 price target.
See the top stocks recommended by analysts >>
Enanta Pharmaceuticals (ENTA)
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals, with a price target of $23.00. The company’s shares closed last Monday at $8.94, close to its 52-week low of $8.08.
According to TipRanks.com, Buchanan is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Enanta Pharmaceuticals with a $20.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MOR:
